A structured review of BPC-157's mechanism, the current state of animal and human data, and dated FDA regulatory context and its verification limits. Historical articles may no longer reflect current regulatory status. Check the cited primary source.
BPC-157 (Body Protective Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Since the early 1990s, it has accumulated one of the largest animal research bodies of any peptide compound — over 544 indexed PubMed citations as of 2026.
BPC-157 activates the VEGFR2/Akt-eNOS signaling axis, which drives angiogenesis — the formation of new blood vessels. This is the primary proposed mechanism behind observed healing effects in preclinical models. It also modulates ERK1/2 signaling for endothelial cell proliferation, suppresses TNF-α, IL-6, and IFN-γ, and shifts macrophage polarization from pro-inflammatory M1 to reparative M2 phenotype.
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy
A 2025 systematic review in Current Reviews in Musculoskeletal Medicine identified 544 articles from 1993–2024, with 36 studies meeting inclusion criteria — 35 preclinical and 1 clinical pilot study. This is a meaningful data point: despite decades of research, essentially no controlled human trial data exists.
The single published human study referenced in the 2025 review was a pilot study with limited scope, not a randomized controlled trial. There are no registered Phase I, II, or III clinical trials for BPC-157 in ClinicalTrials.gov as of March 2026.
This creates the central tension in BPC-157 research: robust and consistent preclinical findings across multiple injury models, zero controlled human evidence.
BPC-157 was added to the FDA's Category 2 bulk drug substance list on September 29, 2023. The FDA's stated rationale: (a) immunogenicity risk for certain routes of administration; (b) complexity of peptide-related impurities and API characterization; (c) no or limited safety-related information for proposed routes.
HHS proposed 503A enforcement discretion (not final). FDA substance context: BPC-157. Named in the proposed HHS 503A enforcement-discretion notice (Federal Register 2026-22192, October 2026). The policy is proposed, not final, and is not FDA approval. FDA's earlier record lists the nomination as withdrawn from Category 2 with potential significant safety risks. Regulatory source checked October 29, 2026. Sources: https://www.federalregister.gov/public-inspection/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Score rationale: Animal-only evidence tier, no human RCTs. Regulatory labels do not establish evidence quality. The strong mechanistic research and large preclinical evidence base earns a 2 rather than 1 — but the absence of human trial data is a hard ceiling.
Full compound profile: peptidex.ai/compounds/bpc-157
*This content is for educational and informational purposes only. Not medical advice. See full Research Disclaimer.*
We email you when the FDA or HHS makes a move on a peptide you care about. Every email links the official source. No spam, no sales.
We don't collect health information. Unsubscribe anytime. Privacy policy